Lawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., et al. (2015) Efficacy and Safety of 12 Weeks Versus 18 Weeks of Treatment with Grazoprevir (MK-5172) and Elbasvir (MK-8742) with or without Ribavirin for Hepatitis C Virus Genotype 1 Infection in Previously Untreated Patients with Cirrhosis and Patients with Previous Null Response with or without Cirrhosis (C-WORTHY): A Randomized, Open-Label Phase 2 Trial. The Lancet, 385, 1075-1086.
https://doi.org/10.1016/S0140-6736(14)61795-5

has been cited by the following article:

• TITLE: Liver Stiffness Measurement Is Useful to Predict Early Recurrence of Hepatocellular Carcinoma after Sustained Virological Responses by Direct Antiviral Agents in Patients with Hepatitis C

  AUTHORS: Noboru Hirashima, Hiroaki Iwase, Masaaki Shimada, Noboru Urata, Etsuko Iio, Yasuhito Tanaka

  KEYWORDS: Hepatitis C Virus Infection, Direct-Acting Antivirals, Hepatocellular Carcinoma, Recurrence, Liver Stiffness Measurement

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.8 No.7, July 27, 2018

  ABSTRACT: Background: Recently, increases in the risk of Hepatocellular carcinoma (HCC) recurrence in patients with hepatitis C virus (HCV) due to the administration of direct antivirals agents (DAA) have been reported. Methods: One hundred and nineteen patients who were treated with DAA and achieved sustained viral response (SVR) were prospectively followed-up for over two years by transient elastography with liver stiffness measurements (LSM). Fourteen out of 119 patients (12%) had a history of being treated for HCC by radiofrequency ablation or resection and achieved complete responses after previous HCC treatments before the initiation of DAA. HCC was diagnosed by contrast-enhanced computed tomography (CT) or enhanced magnetic resonance imaging (MR). CT or MR was performed before the DAA treatment and every 6 months after during the follow-up. LSM was performed at the initiation of DAA (LSM0), at 24 weeks after the start of DAA (LSM24), at 48 weeks after that (LSM48) and at 2 years after that (LSM2y). Results: LSM0, LSM24, LSM48 and LSM2y of 105 patients without HCC were 7.5 (3.027.0), 6.0 (2.5 - 31.6), 4.6 (2.6- 25.2) and 4.4 (3.1 - 29.9) kPa, respectively, showing significant improvements. Three out of 105 patients (2.9%) subsequently developed HCC and their LSM showed improvements. Eight out of fourteen patients (57%) with a history of HCC treatments subsequently developed HCC recurrence. LSM0 in the eight patients with recurrence increasing from 12.1 to 27.0 kPa, LSM24 from 9.9 to 26.6 kPa and LSM48 from 9.6 to 18.0 kPa. On the other hand, the six other patients without recurrence had LSM values that were less than 12.0 kPa at last. Based on the ROC analysis, LSM0 15.4, LSM24 12.8 and LSM48 9.6 kPa were identified as cut-off values. Conclusion: HCV patients previously treated for HCC with high LSM values before and after DAA have an elevated risk of HCC recurrence, particularly LSM24 >12.8 kPa and LSM48 >9.6 kPa.